標(biāo)題: Titlebook: Biobetters; Protein Engineering Amy Rosenberg,Barthélemy Demeule Book 2015 American Association of Pharmaceutical Scientists 2015 drug tar [打印本頁(yè)] 作者: 涌出 時(shí)間: 2025-3-21 18:15
書(shū)目名稱Biobetters影響因子(影響力)
書(shū)目名稱Biobetters影響因子(影響力)學(xué)科排名
書(shū)目名稱Biobetters網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱Biobetters網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱Biobetters被引頻次
書(shū)目名稱Biobetters被引頻次學(xué)科排名
書(shū)目名稱Biobetters年度引用
書(shū)目名稱Biobetters年度引用學(xué)科排名
書(shū)目名稱Biobetters讀者反饋
書(shū)目名稱Biobetters讀者反饋學(xué)科排名
作者: conifer 時(shí)間: 2025-3-21 21:29
https://doi.org/10.1007/978-94-009-2007-1ure that can mediate biological response upon specifically binding to an antigen. This chapter introduces readers to the chemical structure of antibodies, with specific focus on the structure of immunoglobulin G (IgG). The chapter also highlights functionally important IgG domains and their susceptibility to chemical degradation.作者: manifestation 時(shí)間: 2025-3-22 01:38 作者: Apraxia 時(shí)間: 2025-3-22 04:59
978-1-4939-4994-6American Association of Pharmaceutical Scientists 2015作者: Ordnance 時(shí)間: 2025-3-22 08:49 作者: 釋放 時(shí)間: 2025-3-22 14:50 作者: 流出 時(shí)間: 2025-3-22 17:05 作者: Disk199 時(shí)間: 2025-3-23 01:00
Studies in History and Philosophy of Sciencessibility that the health of patients might be improved by the administration of purified exogenous enzyme. Glucocerebrosidase for this investigation was originally obtained from human placental tissue. Intravenous administration of this enzyme to patients with Gaucher disease reduced the amount of 作者: Ankylo- 時(shí)間: 2025-3-23 01:37
https://doi.org/10.1007/978-3-031-51258-2 MPS IV, MPS VI, Gaucher disease, Fabry disease, and Pompe disease. The therapeutic enzyme replacement effectively lowers substrate accumulation and has dramatically improved lifespan, increased overall quality of life, and diminished the extent of organ involvement in these conditions. Despite this作者: IRATE 時(shí)間: 2025-3-23 08:15 作者: rectocele 時(shí)間: 2025-3-23 12:37
Restatement and Propositions (1968)ugh 75 % of the LSDs affect the central nervous system (CNS), the replacement enzymes are large molecules that do not cross the blood–brain barrier (BBB), and, thus, ERT is not an effective therapy for the CNS manifestations of the disease. The brain and spinal cord can be treated if the enzyme is r作者: PLIC 時(shí)間: 2025-3-23 16:00 作者: 發(fā)生 時(shí)間: 2025-3-23 18:42 作者: 柔聲地說(shuō) 時(shí)間: 2025-3-23 22:18
The New Synthese Historical Library protein therapeutics. However, advantage has been taken of this phenomenon for formulation of slow-release products such as the long-acting insulin analog, Lantus. or the peptidic gonadotropin-releasing hormone receptor blocker, Firmagon.. Aggregation in vivo may also take place after intravenous (作者: municipality 時(shí)間: 2025-3-24 04:10
,Die Computer in Princeton, 1946–1952,r, highly susceptible to chemical modifications that can affect their potency and predispose patients to adverse immunogenic responses. This chapter presents the common routes of hydrolytic degradation of mAbs, their effects on in vivo performance, and the various strategies used to overcome these e作者: 胎兒 時(shí)間: 2025-3-24 09:43
Lebensgeschichten aus der Wissenschaft been associated with a large number of pathologies (Guttmann and Ghoshal 2011; Martinez et al. 2010; Nakamura et al. 2012) as well as biological aging (Stadtman 1988, 1992; Oliver et al. 1987). Protein oxidation can lead to changes in activity, conformation, protein–protein interactions, and half-l作者: 坦白 時(shí)間: 2025-3-24 12:12 作者: patriarch 時(shí)間: 2025-3-24 17:14 作者: AGOG 時(shí)間: 2025-3-24 20:29 作者: 獨(dú)輪車 時(shí)間: 2025-3-25 00:29
,The Gathering Storm – “A Shower of Fishes”,asis on recent advances in the design and manipulation of functional Ig fragments for therapeutic applications. Currently, the challenge is to create next generation types of antibodies that offer improvements over classical MAbs with regard to biomolecular attributes and clinical performance. Bispe作者: 成績(jī)上升 時(shí)間: 2025-3-25 04:16
Walter Prenowitz,James Jantosciakd/or high dosing to achieve clinical efficacy. A favorite strategy to create biobetters both from approved biologicals and based on new protein or peptide drug candidates is to prolong their time in circulation. This can be accomplished in two ways, either by conferring binding activity towards the 作者: 比賽用背帶 時(shí)間: 2025-3-25 11:15 作者: Range-Of-Motion 時(shí)間: 2025-3-25 14:30
Studies in History and Philosophy of Scienceof its glycoform for the successful treatment of patients with Gaucher disease. The steps involved in this endeavor and benefit of appropriately modified glucocerebrosidase for patients with Gaucher disease are chronicled.作者: 思考才皺眉 時(shí)間: 2025-3-25 19:19 作者: 祖先 時(shí)間: 2025-3-25 20:49
Book 2015 It is based on the fact that though numerous important therapeutic protein products have been developed for life threatening and chronic diseases that possess acceptable safety and efficacy profiles, these products have generally not been reexamined and modified for an improved clinical performance作者: Canvas 時(shí)間: 2025-3-26 04:02
2210-7371 erapeutic enzymes and monoclonal antibodies - as examples of“Biobetters: Protein Engineering to Approach the Curative” discusses the optimization of protein therapeutic products for treatment of human diseases. It is based on the fact that though numerous important therapeutic protein products have 作者: 虛情假意 時(shí)間: 2025-3-26 05:21 作者: 解決 時(shí)間: 2025-3-26 08:58 作者: Suggestions 時(shí)間: 2025-3-26 12:44
https://doi.org/10.1007/978-3-658-04064-2obetters, and describe various strategies recently employed by biopharmaceutical firms. We conclude by considering issues involving immunogenicity of biologics, as well as controversies regarding whether biosimilars should have identical international non-proprietary names as the reference brand.作者: 責(zé)怪 時(shí)間: 2025-3-26 17:09
Biosimilar and Biobetter Scenarios for the US and Europe: What Should We Expect?obetters, and describe various strategies recently employed by biopharmaceutical firms. We conclude by considering issues involving immunogenicity of biologics, as well as controversies regarding whether biosimilars should have identical international non-proprietary names as the reference brand.作者: Nonporous 時(shí)間: 2025-3-26 23:03
Challenges of Enzyme Replacement Therapy: Poor Tissue Distribution in Lysosomal Diseases Using Pomperidging the gap between currently available therapies and a cure for LSDs are best viewed through the lens of our collective experience with Pompe disease. While ERT dramatically improved the prognosis in both infantile and later onset forms of Pompe disease, several limitations exist: the inefficie作者: 評(píng)論性 時(shí)間: 2025-3-27 01:38 作者: 無(wú)法解釋 時(shí)間: 2025-3-27 06:19 作者: NAIVE 時(shí)間: 2025-3-27 11:10 作者: maroon 時(shí)間: 2025-3-27 15:35
Prediction of Aggregation In Vivo by Studies of Therapeutic Proteins in Human Plasmamixing Herceptin. and Avastin. in 5 % dextrose alone failed to reveal aggregates. However, mixing these formulations with human plasma resulted in the formation of large aggregates. No such aggregation was observed when the antibodies were formulated in 0.9 % NaCl and mixed with human plasma. The ag作者: 繁殖 時(shí)間: 2025-3-27 18:28
Oxidation of Proteins in the In Vivo Environment: What We Know; What We Need to Study and Potential -epitopes cross-react with native, unmodified proteins, breaking immune tolerance (Griffiths 2008; Omersel et al. 2008, 2011; van Beers et al. 2011; Sauerborn et al. 2010; Jiskoot et al. 2009; Schellekens and Jiskoot 2006). Here, autoantibody generation may lead to autoimmune disorders. Analogous to作者: chastise 時(shí)間: 2025-3-28 00:07 作者: Endemic 時(shí)間: 2025-3-28 02:05 作者: Exclaim 時(shí)間: 2025-3-28 06:24
Antibody-Like Molecules Designed for Superior Targeting and Pharmacokinetics incorporating additional mechanisms of action, including altered effector function against established therapeutic targets. These molecules are commonly termed biobetters, which, formally speaking, are biologic drugs that are developed against previously validated target antigens but have some prop作者: Embolic-Stroke 時(shí)間: 2025-3-28 12:33 作者: Offensive 時(shí)間: 2025-3-28 14:45 作者: Tracheotomy 時(shí)間: 2025-3-28 21:43 作者: Frisky 時(shí)間: 2025-3-29 01:52 作者: 在駕駛 時(shí)間: 2025-3-29 04:10 作者: AIL 時(shí)間: 2025-3-29 07:23
Restatement and Propositions (1968)ase (IDUA) lysosomal enzyme, and MPS Type II is caused by mutations in the iduronate 2-sulfatase (IDS) lysosomal enzyme. Both of these diseases have prominent CNS manifestations. This chapter describes biobetter forms of these recombinant enzymes, and the drug development of IgG-IDUA and IgG-IDS fus作者: occurrence 時(shí)間: 2025-3-29 11:52
Event Handling with the Swing Component Set,us, in spite of having an effective treatment for Pompe disease, there remains a critical unmet medical need for a less immunogenic GAA, especially for CRIM-negative babies. New methods for inducing tolerance to GAA have been developed in recent years, which are reviewed here. They include drug-indu作者: 閑聊 時(shí)間: 2025-3-29 16:16
The New Synthese Historical Librarymixing Herceptin. and Avastin. in 5 % dextrose alone failed to reveal aggregates. However, mixing these formulations with human plasma resulted in the formation of large aggregates. No such aggregation was observed when the antibodies were formulated in 0.9 % NaCl and mixed with human plasma. The ag作者: 無(wú)力更進(jìn) 時(shí)間: 2025-3-29 23:31
Lebensgeschichten aus der Wissenschaft-epitopes cross-react with native, unmodified proteins, breaking immune tolerance (Griffiths 2008; Omersel et al. 2008, 2011; van Beers et al. 2011; Sauerborn et al. 2010; Jiskoot et al. 2009; Schellekens and Jiskoot 2006). Here, autoantibody generation may lead to autoimmune disorders. Analogous to作者: 撫育 時(shí)間: 2025-3-30 03:50
Vienna Circle Institute Yearbook and delivery and inform regarding potential liabilities that may be associated with the lead molecule. For biobetters, MA studies also ensure that the lead molecule is indeed “better” with respect to the selected attribute. This chapter outlines the MA strategy, the results of which dictate decisio作者: 不能和解 時(shí)間: 2025-3-30 06:53
https://doi.org/10.1057/9780230373440r efficacy profile (Foye, Lippincott Williams & Wilkins, Philadelphia, 2008). As a result of protein aggregation or degradation, therapeutic activity can be decreased, increased, or altered to have off-target effects. Protein degradation or aggregation could be facilitated under inflammatory circums作者: 聯(lián)合 時(shí)間: 2025-3-30 09:31 作者: dapper 時(shí)間: 2025-3-30 12:58
,The Gathering Storm – “A Shower of Fishes”, combinations and, thus, likely enable unique therapeutic modes of action to yield promising biobetters. The four most advanced scaffold technologies, Adnectins, Affibodies, Anticalins and DARPins, which were developed beyond the academic research stage and have reached clinical studies, constitute
